SwansonECSchliessMR.Congenital cytomegalovirus infection: new prospects for prevention and therapy. Pediatr Clin North Am. 2013;60:335-349.
2.
HamiltonSTvan ZuylenWShandA. Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: a systematic review. Rev Med Virol. 2014;24:420-433.
3.
KimberlinDWJesterPMSánchezPJ.Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med. 2015;372:933-943.
4.
AcostaEPBrundageRCKingJR. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation. Clin Pharmacol Ther. 2007;81:867-872.
5.
MarshallBCKochWC.Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events. Paediatr Drugs. 2009;11:309-321.
6.
KadambariSWilliamsEJLuckSGriffithsPDSharlandM.Evidence based management guidelines for the detection and treatment of congenital CMV. Early Hum Dev. 2011;87:723-728.
7.
ChoiKYSharonBBalfourHHJrBelaniKPozosTCSchleissMR.Emergence of antiviral resistance during oral valganciclovir treatment of an infant with congenital cytomegalovirus (CMV) infection. J Clin Virol. 2013;57:356-360.
8.
CampaniniGZavattoniMCristinaEGazzoloDStronatiMBaldantiF.Multiple ganciclovir-resistant strains in a newborn with symptomatic congenital human cytomegalovirus infection. J Clin Virol. 2012;54:86-88.
9.
KampmannSESchindeleBApeltL. Pyrosequencing allows the detection of emergent ganciclovir resistance mutations after HCMV infection. Med Microbiol Immunol. 2011;200:109-113.
